An acid-buffering bioadhesive vaginal tablet was developed for the treatment of genitourinary tract infections. From the bioadhesion experiment and release studies it was found that polycarbophil and sodium carboxymethylcellulose is a good combination for an acid-buffering bioadhesive vaginal tablet. Sodium monocitrate was used as a buffering agent to provide acidic pH (4.4), which is an attribute of a healthy vagina. The effervescent mixture (citric acid and sodium bicarbonate) along with a superdisintegrant (Ac-Di-sol) was used to enhance the swellability of the bioadhesive tablet. The drugs clotrimazole (antifungal) and metronidazole (antiprotozoal as well as an antibacterial) were used in the formulation along with Lactobacillus acidophilus spores to treat mixed vaginal infections. From the ex vivo retention study it was found that the bioadhesive polymers hold the tablet for more than 24 hours inside the vaginal tube. The hardness of the acidbuffering bioadhesive vaginal tablet was optimized, at 4 to 5 kg hardness the swelling was found to be good and the cumulative release profile of the developed tablet was matched with a marketed conventional tablet (Infa-V). The in vitro spreadability of the swelled tablet was comparable to the marketed gel. In the in vitro antimicrobial study it was found that the acid-buffering bioadhesive tablet produces better antimicrobial action than marketed intravaginal drug delivery systems (Infa-V, Candid-V and Canesten 1).
INTRODUCTION
Vaginitis is a common gynecological problem in women of all age groups. It may result from microbial infections, contact dermatitis, atrophic vaginitis, or allergic reactions. 1 The infectious vaginitis is of 3 types: candidiasis, trichomoniasis, and bacterial vaginosis. Vaginal infections are usually characterized by vaginal discharge, vaginal irritation or vulvar itching, and vaginal odor. 2, 3 Vaginal infections are diagnosed by vaginal discharge, pH measurement, and microscopic examination. 2 In bacterial vaginosis and trichomoniasis, the pH of vaginal secretions is reported to rise. 2 Several drug delivery systems are used for contraception, vaginal infections, and vaginal health and hygiene maintenance. Marketed vaginal dosage forms include tablets, tampons, films, sponges, foams, creams, gels, solutions, ointments, ovules, soft gelatin capsules, pessaries, douches, suppositories, and vaginal rings. 4, 5 Tablets and gels are the most common vaginal formulations. The conventional drug delivery systems (exemplified by tablets, creams, gels, pessaries, and foams) suffer from poor retention in the vaginal tract, as they are removed in a short time by the tract's self-cleansing action. 6 Multiple daily doses of conventional formulations result in poor patient compliance. To overcome such problems, delivery systems with bioadhesive polymers that prolong drug permanence on the vaginal mucosa were developed. Such systems have increased patient compliance as well as therapeutic success. 7, 8 Hence, the present work was envisaged to develop a stable, novel, and aesthetic bioadhesive vaginal delivery system with improved efficacy. The following bioadhesive polymers were screened to develop a vaginal delivery system: polycarbophil, carbopol, sodium carboxymethylcellulose, sodium alginate, xanthan and guar gums, hydroxypropyl cellulose, and hydroxypropyl methylcellulose. The polymers hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, and xanthan and guar gums have good stability at pH 3 to 10 and, hence, are good candidates for vaginal delivery systems (pH 4 to 4.5). Clotrimazole is a Food and Drug Administration (FDA)-approved over-the-counter (OTC) antifungal drug; metronidazole is an FDA-approved antibacterial drug for vaginal infections. Clotrimazole and metronidazole are broad-spectrum antibiotics recommended for treatment of candidiasis and bacterial vaginosis/trichomoniasis, respectively. [1] [2] [3] Lactobacilli are normal microflora of the vaginal tract responsible for the acidic pH of the vagina. 1, 9 Hence, it was thought to be worthwhile to include spores of Lactobacillus acidophilus in the formulation to be developed.
MATERIALS AND METHODS
Drugs and polymers were obtained as gift samples from Indian pharmaceutical firms (metronidazole, clotrimazole, and Lactobacillus acidophilus spores from Lark Laboratories [Bhiwadi, Rajasthan, India]; bioadhesive polymers from Ranbaxy [Gurgaon, Haryana, India]; and sodium monocitrate from Oscar Laboratories [New Delhi, India]). Infa-V vaginal tablets (a combined formulation of clotrimazole, metronidazole, and Lactobacillus acidophilus) were purchased from a Chemist shop. Instruments used were a texture analyzer (TAXT2i/; Stable Micro Systems, Surray, UK), surface pH electrode (Orion 9135AP; Thermoelectron Corporation, Ecublens, Switzerland), Shimadzu UV-Spectrophotometer 1601 (Shimadzu, Singapore Science Park, Singapore), 16-station rotary tablet machine (Clit, Amedabad, India), and BOD incubator (Nirmal International, New Delhi, India).
Development of Bioadhesive Tablet
Bioadhesive tablets were formulated by using polymers alone and in combination. The tablet compositions were compressed directly on a 16-station rotary tablet machine by using 16-mm flat-faced round punches. The composition formulas for the bioadhesive tablets are given in Table 1 .
Preparation of Simulated Vaginal Fluid
The simulated vaginal fluid (pH 4.2) was prepared as described by Owen and Katz. 10 
Method for Estimation of Drugs
Clotrimazole and metronidazole were individually estimated at 2 different wavelengths (λ max ). A new colorimetric method was developed for estimating clotrimazole: Samples containing clotrimazole were diluted using 70% wt/wt perchloric acid and heated for 5 minutes on a boiling water bath. The intensity of the resultant yellow color tint was estimated at 448 nm. In test solutions of clotrimazole in perchloric acid (70% wt/wt), the percentage of methanol/water must not exceed 8.0% (vol/vol), otherwise the intensity of the color development decreases. For estimation of metronidazole, samples were prepared in distilled water and absorbance recorded at 320 nm.
Validation of Analytical Method
Analytical methods were validated for accuracy, recovery, precision, linearity, and limit of detection (LOD) / limit of quantitation (LOQ) determinations.
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Evaluation of Bioadhesive Tablets
Tablets were evaluated on the basis of bioadhesive strength, release properties, and hardness. The bioadhesive strength was measured using a texture analyzer. Dissolution studies were performed in 900-mL dissolution media (0.5% sodium laurylsulphate [SLS] wt/vol in distilled water) using a 6-vessel dissolution rate test apparatus (USP II) at 50 rpm and 37 ± 0.5-C. The hardness of the bioadhesive tablet was measured by using a Pfizer hardness tester D6426 (New Delhi, India).
In Vitro Adhesion Tests
The mucoadhesive properties of tablet formulations were assessed on the vaginal mucosa of buffalo using a texture analyzer (pretest and test speeds: 0.5 and 0.1 mm per second, respectively, contact 3.0-minutes, contact force 1.0 Newton, Table 1 . Tablet formulations of metronidazole (500 mg) and clotrimazole (100 mg)
Ingredients
Tablets formulations (quantity in mg) and load cell 500 Newtons). Vaginal mucosa free from supporting tissues was stored in a deep freezer at -20-C. For experiments, the vaginal tube (thawed in normal saline with 0.1% wt/vol sodium azide preservative) was incised longitudinally and held on the lower platform of the texture analyzer. The tablet was applied to the upper probe with the help of a double-sided adhesive tap ( Figure 1 ). The vaginal mucosa was moistened with simulated vaginal fluid. The force required to detach the formulation from the tissue surface was determined as the peak value in resultant force-time plot (as shown in the graph in Figure 2 ).
T-1 T-2 T-3 T-4 T-5 T-6 T-7 T-8 T-9 T-10 T-11 T-12 T-13 T-14 T-15 T-16 T-17
HPMC-K 4M 72 - - - - - - - - - - - - - - - - HPMC-K 15M - 72 - - - - - - - - - - - - - - - HPMC-100cp - - 72 - - - - - - - - - - - - - - Xanthan gum - - - 72 - - - - - - - - - - - 36 - Sod. Alginate - - - - 72 - - - - - - - - - - - - HPC (M) - - - - - 72 - - - - - - - - - - - Sod. CMC - - - - - - 72 - - - 36 - - - 36 - - Carbopol-971 - - - - - - - 72 - - 36 36 36 - - - - Polycarbophil - - - - - - - - 72 - - - - 36 36 36 36 Guar gum - - - - - - - - - 72 - - 36 36 - - - HPMC-5 cp - - - - - - - - - - - 36 - - - - 36 Sod bicarbonate - - - - - - -
Development of the Acid-buffering Bioadhesive Tablet
The compositions (Table 2) were directly compressed on the rotary machine by using flat-faced round punches.
pH of Tablet Formulation
The acid-buffering bioadhesive tablet was kept in 2 mL distilled water and the pH of the swelled tablet was measured.
The conventional tablet was crushed into a powder and dissolved in 2 mL of distilled water. The tip of the electrode was brought into contact with the wet mass of the conventional tablet for pH measurement.
Optimization of Tablets
The acid-buffering bioadhesive tablet was optimized on the basis of hardness, bioadhesion, and release profile. The release profile of the bioadhesive formulations was studied in 900 mL of simulated vaginal fluid containing 0.5% wt/vol sodium lauryl sulfate using USP dissolution II apparatus at 50 rpm and 37-C.
Apparatus for Ex Vivo Retention Studies
The apparatus for ex vivo bioadhesion/retention studies consisted of a glass cell (length 11.0 cm; external diameter 5.0 cm; internal diameter at upper and lower ends: 2.4 and 1.0 cm respectively) open at both the ends ( Figure 3 ). The edges of the upper and lower ends were tapered to tie the tissue properly. The cell had 2 small side arms (lower as inlet and upper as outlet) separated by a distance of 4.5 cm. Distilled water circulated through these side arms into the glass cell by using a pump (Miellins, India). Peristaltic pumps were used to circulate simulated vaginal fluid/distilled water at 37-C. This assembly was a modified version of the Setnikar and Fantelli apparatus.
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Ex Vivo Retention Measurement
Ex vivo retention studies were performed by using the assembly shown in Figure 3 . The excised and cleaned buffalo vaginal tube was vertically suspended in the glass cell. The ends of the vaginal tube were averted on the tapering of the upper and lower ends of the glass cell and crimped using rubber bands. Water was circulated in the cell to maintain temperature equivalent to body temperature and also to keep the tissue moist. The bioadhesive tablet was inserted into the tube using a pair of blunt forceps. A preload time of 5 minutes was allowed to help the formulation adhere properly to the vaginal walls.
Simulated vaginal fluid (3 mL/h) was allowed to fall dropwise into the vertically suspended vaginal tube. Expulsion of formulation was recorded from the lower end of the cell.
Measurement of Spreadability of the Tablet
The acid-buffering bioadhesive tablet was allowed to swell in 2 mL of distilled water; the swollen mass was gently transferred to the center of a glass plate and compressed under several glass plates (100 ± 5 g each, every 1 minute) and the spread diameters (Figure 4 ) recorded each time. 13 In Vitro Antifungal Studies
In vitro antifungal studies were performed against Candida albicans in Sabouraud's agar medium by the cup plate method. The cups cut in the inoculated solidified media were filled with different formulations using sterilized syringes. The marketed tablet was crushed into a powder and dissolved in 2 mL of sterilized water in a sterilized syringe. The marketed gels were applied using the sterilized syringe. The developed acid-buffering bioadhesive tablet was swelled in 2 mL of sterile water applied into the cups. The covered petriplates were incubated at 32-C in the BOD incubator for 40 hours. The zone of inhibition was measured at the end of 40 hours.
RESULTS AND DISCUSSION
Characterization of Bioadhesive Tablets
White, round, flat disc-shaped bioadhesive tablets (diameter 16.1 mm, thickness 5.1 mm) were compressed and the results of hardness and bioadhesive strength are presented in Table 3 .
Validation of Analytical Method
The recoveries of clotrimazole and metronidazole by the proposed spectrophotometric method were 100.795% ± 0.380% and 99.660% ± 0.310% respectively. The percent precision for clotrimazole was 100.240% ± 0.461% and for metronidazole 99.490% ± 0.429%. LOD/LOQ values (μg/mL) 
E4
were found to be 0.14/0.46 (metronidazole) and 0.188/0.590 clotrimazole). The linearity was 1 to 20 μg/mL (metronidazole) and 0.5 to 10.0 μg/mL (clotrimazole). Tablets   Table 4 shows the cumulative percent release profiles of tablet formulation T-1 to T-17. Tablets (T-1 to T-10) contained single bioadhesive polymer (6% wt/wt). Tablets T-1, T-2, and T-3 (with different grades of hydroxypropyl methylcellulose [HPMC]) showed sustained release as per individual viscosity grades (100 cp 9 K4M 9 K15M). Drugs were completely released within 5
Release Studies of Bioadhesive
hours (T-4 and T-5). T-4 and T-5 (sodium carboxymethylcellulose [CMC] and hydroxypropyl cellulose [HPC]
[M] respectively) were more errodable resulting in less prolonged release. The typical T-7 release profile was possibly because of the rigid gel-forming capacity and less errodability of sodium alginate. T-8 (guar gum) swelled rapidly in contact with water and formed rigid gel and resulted in sustained release. T-9 and T-10, containing carbopol and polycarbophil respectively, had less sustained release. Moreover, total drug content (T-9 and T-10) dissolved within 3 hours as tablets disintegrated before polymers could react (or neutralize) with sodium bicarbonate to form the gel. T-11 and T-12 (sodium CMC and HPMC-5cp respectively) swelled rapidly when in contact with water to form gel. This action of sodium CMC and HPMC prevented fast disintegration of the tablet and allowed sufficient time for neutralization of carbopol and formation of prolonged release gel. T-13 exhibited sustained release by the same mechanism as T-11 and T-12 but slow release was due to the presence of the gel structure forming guar gum. T-14 to T-17 swelled in dissolution medium preventing fast disintegration of tablets and provided sufficient time for polycarbophil to gel. The sustained release of T-15 and T-17 was completed in 5 hours while the release profiles of T-14 and T-16 were very slow because of guar and xanthan gums.
Bioadhesive Strength
Bioadhesive strengths of the formulations were determined (Table 3 ; Figure 2 as representative graph). On the basis of bioadhesive strength and dissolution release studies, T-15 comprising polycarbophil and sodium carboxymethyl cellulose was considered a good candidate for development as an acid-buffering bioadhesive tablet. The good bioadhesion of polycarbophil and fast swelling of sodium CMC provided a good combination of bioadhesive polymers for further development. Fast swellability of sodium CMC prevented the premature disintegration of polycarbophil tablet and polycarbophil prevented the fast erosion of sodium CMC.
Acid-buffering Bioadhesive Vaginal Tablet
The composition of the tablet (Table 2 ) maintained an acidic pH (4.4), which is a desirable attribute of the formulations used to treat vaginal infections. Sodium monocitrate was used as an acidifying/buffering agent. Lactobacilli were also included to compensate for loss of microflora in vaginal infections or during use of antibiotics. The effervescent composition of sodium monocitrate and sodium bicarbonate along with superdisintegrant helped the tablet to swell and thereafter soften.
The pH of the acid-buffering bioadhesive tablet was found to be acidic (4.40 ± 0.092, n = 3), almost similar to the required pH of the tract. The pH of 2 other marketed formulations was also acidic (Infa-V = 5.23 ± 0.246 and Canesten-V 6 = 4.88 ± 0.085, n = 3 each).
The acid-buffering bioadhesive tablet was optimized on the basis of hardness, release profile, and bioadhesive strength. The cumulative drug release (%) decreased with an increase in the hardness of the tablet. The higher hardness (95 kg) decreased the swellability of the acid-buffering bioadhesive tablet because water did not penetrate into the tablet and effervescent mixture and superdisintegrant did not act properly. The release of acid-buffering bioadhesive vaginal tablet (hardness 4 to 5 kg) was comparable to Infa-V but the release profile of the bioadhesive tablet (hardness 5 to 6 kg) was slower than that of Infa-V (Table 5) . Hardness (4 to 5 kg) was found to be optimum for the acid-buffering bioadhesive tablet. In vitro bioadhesive strength of the acid-buffering bioadhesive vaginal tablet was 0.322 to 0.335 N. The tablet showed very good retention (9 24 hours) in the ex vivo experiment. The tablet softened inside the vaginal tube after absorbing simulated vaginal fluid and became a swollen structure, helping it to adhere to the vaginal mucosa. Swollen bioadhesive polymers held the solid content of the tablet inside the vagina; at the same time preventing premature leakage. The weight of the tablet (1.2 g) also favored prolonged retention of the tablet inside the tract against gravity. Infa-V disintegrated inside the vagina and its content started leaking after 5 to 8 hours. The spreadability of the acid-buffering bioadhesive vaginal tablet was comparable to Candid-V gel (Figure 4 ).
Antifungal Studies
The acid-buffering bioadhesive tablet had better antimicrobial activity as compared with the marketed formulations (Infa-V tablet, Canesten 1, and Candid V-gel). The developed vaginal tablet contained clotrimazole, metronidazole, and Lactobacilli along with the acidic buffering agent sodium monocitrate. The composition might have synergized antimicrobial actions of the bioadhesive tablet. Bioadhesive polymers of the tablet had prolonged drug release and provided better contact with the wells cut in the plate, while the Infa-V suspension dried up as water was not available in the wells for prolonged time to allow diffusion of drug molecule(s). The results of antifungal studies are reported in Table 6 .
CONCLUSION
Polycarbophil and sodium carboxymethyl cellulose are the polymers of choice for bioadhesive vaginal tablets. Ex vivo retention studies justified the prolonged retention of the tablet inside the vaginal tract. It can be concluded that the acidbuffering bioadhesive vaginal tablets are more effective as well as having better patient compliance than existing conventional vaginal drug delivery systems. 
